Agomab Says Phase 1 Data In 10 IPF Patients Show Favorable Safety, Target Engagement For Inhaled AGMB-447; Submits CTA For 120-Patient Phase 2 INSPIRIA Study, Targets Start In H2 2026

뉴스 본문을 불러오고 있어요.

Agomab Says Phase 1 Data In 10 IPF Patients Show Favorable Safety, Target Engagement For Inhaled AGMB-447; Submits CTA For 120-Patient Phase 2 INSPIRIA Study, Targets Start In H2 2026 | 웨이프 WAPE

Agomab Says Phase 1 Data In 10 IPF Patients Show Favorable Safety, Target Engagement For Inhaled AGMB-447; Submits CTA For 120-Patient Phase 2 INSPIRIA Study, Targets Start In H2 2026

기사 요약

관련 종목

댓글 —